Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine
(Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease
during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.